Contingency Management for Opioid and Stimulant Use Disorders in Primary Care
Opioid Use Disorder, Stimulant Use Disorder
About this trial
This is an interventional treatment trial for Opioid Use Disorder focused on measuring opioid use disorder, stimulant use disorder, contingency management, primary care, addiction medicine, buprenorphine
Eligibility Criteria
Inclusion Criteria:
- At least 18 years of age
- Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder
- Recently initiated medications for opioid use disorder (MOUDs) at Broadway Family Medicine (BFM), within 2 weeks of recruitment
- Have an active prescription for buprenorphine-naloxone (Suboxone)
Exclusion Criteria:
- Prescription for an amphetamine would exclude patients from the abstinence-based CM, but they could participate in the attendance-only CM.
- Dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.
Sites / Locations
- University of Minnesota
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Experimental
Experimental
Treatment as usual (TAU)
Attendance-only CM
Attendance + abstinence CM
These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months.
Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments.
Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program.